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Abstract
Background: Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate
metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy
with Vγ2Vδ2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials
and preclinical studies have used continuous zoledronate exposure to expand Vγ2Vδ2 cells where zoledronate is
slowly diluted over the course of the culture. Zoledronate inhibits farnesyl diphosphate synthase (FDPS) in
monocytes causing isopentenyl pyrophosphate to accumulate that then stimulates Vγ2Vδ2 cells. Because
zoledronate inhibition of FDPS is also toxic for T cells, we hypothesized that a short period of exposure would
reduce T cell toxicity but still be sufficient for monocytes uptake. Additionally, IL-15 increases the anti-tumor activity
of murine αβ T cells in mice but its effect on the in vivo anti-tumor activity of human Vγ2Vδ2 cells has not been
assessed.
Methods: Human Vγ2Vδ2 T cells were expanded by pulse or continuous zoledronate stimulation with IL-2 or IL-15.
Expanded Vγ2Vδ2 cells were tested for their expression of effector molecules and killing of tumor cells as well as
their in vivo control of human prostate cancer tumors in immunodeficient NSG mice.
Results: Pulse zoledronate stimulation with either IL-2 or IL-15 resulted in more uniform expansion of Vγ2Vδ2 cells
with higher purity and cell numbers as compared with continuous exposure. The Vγ2Vδ2 cells had higher levels of
CD107a and perforin and increased tumor cytotoxicity. Adoptive immunotherapy with Vγ2Vδ2 cells derived by
pulse stimulation controlled human PC-3 prostate cancer tumors in NSG mice significantly better than those
derived by continuous stimulation, halting tumor growth. Although pulse zoledronate stimulation with IL-15
preserved early memory subsets, adoptive immunotherapy with IL-15-derived Vγ2Vδ2 cells equally inhibited PC-3
tumor growth as those derived with IL-2.
Conclusions: Pulse zoledronate stimulation maximizes the purity, quantity, and quality of expanded Vγ2Vδ2 cells
for adoptive immunotherapy but there is no advantage to using IL-15 over IL-2 in our humanized mouse model.
Pulse zoledronate stimulation is a simple modification to existing protocols that will enhance the effectiveness of
adoptively transferred Vγ2Vδ2 cells by increasing their numbers and anti-tumor activity.
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Background
Cancer is the second leading cause of deaths in the
United States and is responsible for 25% of all deaths.
Despite advances in our understanding of its causes,
treatment had been limited for many tumor types. How-
ever, recent successes in cancer immunotherapy are
revolutionizing treatment. Intrinsic T cell immunity
against tumors can be released by using mAbs to remove
inhibition by checkpoint CTLA-4 and PD-1 receptors
resulting in responses to many types of tumors. Adoptive
immunotherapy with T cells expressing chimeric antigen
receptors (CAR) or tumor-reactive αβ T cell antigen
receptors (TCRs) have resulted in cures. Yet, significant
limitations exist for these therapies. CAR-T therapy is
limited to tumors expressing proteins that allow their
specific targeting. This has limited their use for solid, non-
hematopoietic tumors [1]. Tumor-specific αβ TCRs are
difficult to identify and therapy must be individualized for
each patient’s MHC. Checkpoint blockade with anti-PD-1
does not work in >75% of lung cancer patients and is even
less effective against other tumors, such as colorectal
carcinomas, that have few neoantigens due to coding
mutations. Although cancer immunotherapy is a break-
through therapy, additional approaches are needed to
realize its full potential.
Treatment with γδ T cells expressing Vγ2Vδ2 TCRs
(also termed Vγ9Vδ2 TCRs) is one such therapy that
shows promise. In contrast to αβ T cells, the response of
human γδ T cells expressing Vγ2Vδ2 TCRs is not MHC
restricted [2] but instead require the immunoglobulin
superfamily protein, butyrophilin 3A1, that is expressed
by all human cells tested [3–7]. Thus, tumor cells and
normal cells from all tissues can serve as presenting cells
for Vγ2Vδ2 cells. γδ T cells bridge innate and adaptive
immunity by using their γδ TCRs in an innate fashion to
recognize unconventional ligands associated with cell
transformation, infections, and inflammation. γδ T cells
expressing Vγ2Vδ2 TCRs are found in primates but not
rodents and play important roles in human immunity to
microbes and tumors. Vγ2Vδ2 T cells expand to very
high numbers during many infections (up to 1 in 2
circulating T cells) and these cells can kill infected cells
and tumor cells as well as secrete inflammatory Th1 cy-
tokines, chemokines, and growth factors. Vγ2Vδ2 T cells
perform these functions by using their TCRs as pattern
recognition receptors that monitor the levels of prenyl
pyrophosphates. Prenyl pyrophosphates are essential inter-
mediates in isoprenoid biosynthesis that is required by
both microbes and humans. The major endogenous stimu-
lator is isopentenyl pyrophosphate (IPP), an intermediate
in the mevalonate pathway, whereas the major microbial
stimulator is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMBPP), an intermediate in the 2-C-methyl-D-
erythritol-4-phosphate pathway (reviewed in Ref. [8]).
Vγ2Vδ2 T cells can also use their Vγ2Vδ2 TCRs to
directly recognize several malignant B cell lines [9–13]
although for the vast majority of tumors there is no direct
recognition. In contrast, treatment of tumor cells with
aminobisphosphonates allows them to stimulate Vγ2Vδ2
T cells by blocking farnesyl diphosphate synthase (FDPS)
(also termed farnesyl pyrophosphate synthase), which
leads to the accumulation of its upstream metabolite, IPP.
The high levels of IPP can then be detected by Vγ2Vδ2 T
cells through their TCRs [14, 15] in a process requiring
BTN3A1 [3, 5, 7, 16]. Vγ2Vδ2 T cells also express a variety
of NK and SLAM receptors that allow them to recognize
and kill certain tumor cell lines [17].
Several cancer immunotherapy treatments have targeted
Vγ2Vδ2 T cells either by stimulating Vγ2Vδ2 T cells in
vivo [18–22] or by expanding them ex vivo for adoptive
transfer [23–31]. Both approaches have had some success
in pilot studies treating patients with lymphoma and
multiple myeloma as well as non-hematopoietic solid
tumors such as prostate and renal cell cancers. However,
stimulation of Vγ2Vδ2 T cells in patients or primates with
intravenous aminobisphosphonates or prenyl pyrophos-
phates and IL-2 results in large expansions of Vγ2Vδ2
T cells that wane rapidly on subsequent immunizations
[32, 33]. In contrast, adoptive immunotherapy with
Vγ2Vδ2 T cells avoids this loss of responsiveness by
using frozen lymphocytes obtained by leukapheresis prior
to zoledronate therapy. This approach allows patients to
be screened to select those that exhibit responsiveness
although the majority of patients respond. Very large
numbers of Vγ2Vδ2 T cells can be obtained with increases
in Vγ2Vδ2 T cell numbers of 400- to 10,000-fold. To date,
adoptive γδ immunotherapy has resulted in a durable
remission in a patient with metastatic renal cancer [34], a
complete remission in a patient with metastatic breast
cancer [26], and stable disease in 50% of advanced lung
cancer patients [35] with relatively little toxicity.
For most clinical trials and preclinical studies, continuous
exposure of PBMC to zoledronate with IL-2 has been used
to expand Vγ2Vδ2 T cells where zoledronate is slowly
diluted over the course of culture [24–26, 30, 36, 37]. Previ-
ously, we found that continuous exposure to zoledronate is
toxic to Vγ2Vδ2 T cells [15]. This toxicity results in the
suboptimal expansion of Vγ2Vδ2 T cells with relatively
narrow dose ranges for all aminobisphosphonates studied.
In contrast, a short period of exposure (pulse) of PBMC to
aminobisphosphonates results in uniform expansions of
Vγ2Vδ2 T cells over a 100-fold concentration range [15].
The cellular toxicity of aminobisphosphonates has been
extensively studied and is due to the loss of the FDPS
downstream metabolites, farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP) and the pro-
duction of a toxic ATP analog, triphosphoric acid 1-
adenosin-5′-yl ester 3-(3-methylbut-3-enyl) ester (ApppI).
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The loss of FDPS metabolites impairs the transfer of
farnesyl or geranylgeranyl chains to the C-termini of small
GTPases, such as RAS, RAP, RAB, and RHO, and the γ
subunit of G protein-coupled receptors that allows them
to anchor to the inner leaflet of membranes and traffic to
their proper subcellular locations to function in signal
transduction. This loss of normal signaling leads to im-
paired function and apoptotic cell death and can be
partially reversed by the addition of farnesol and/or gera-
nylgeraniol [38–40]. Similarly, the addition of GGPP and
IL-18 to purified Vγ2Vδ2 T cells prevents zoledronate
toxicity and allows their stimulation [41]. However, these
effects were primarily observed with purified Vγ2Vδ2
T cells and these compounds are not approved for
clinical use. Unlike prenyl pyrophosphates, zoledro-
nate is not catabolized so its toxicity persists for the
culture period as it is slowly diluted. Additionally, the
accumulation of IPP leads to the production of the
toxic ATP analog, ApppI, that can directly induce
apoptosis through inhibition of the mitochondrial
adenine nucleotide translocase [42, 43].
Besides bisphosphonate toxicity, an additional factor
that could influence the results of adoptive therapy with
Vγ2Vδ2 T cells is the γC growth cytokine used during
culture. Present adoptive immunotherapy trials have
used IL-2 with zoledronate for Vγ2Vδ2 T cell expan-
sion. However, in mice, CD8 αβ T cells expanded ex
vivo using IL-15 [44, 45] or IL-7/IL-15 [46] rather than
IL-2, mediate increased tumor immunity. Increases in
tumor immunity have been postulated to be due to in-
creases in early/central memory CD8 αβ T cells given
that these cells provide better anti-tumor immunity
compared to late memory cells [47]. We had earlier
shown that IL-15 also supports Vγ2Vδ2 T cell prolifera-
tion in response to IPP and, in combination with IL-12,
increases IFN-γ production [48]. Thus, expanding
Vγ2Vδ2 T cells with IL-15 rather than IL-2 could have
benefits but this possibility has not been tested in vivo
in humanized mouse models.
In this study, we have compared expanding Vγ2Vδ2 T
cells by pulse zoledronate exposure to expanding
Vγ2Vδ2 cells by continuous exposure with either IL-2 or
IL-15. We find that expanding Vγ2Vδ2 T cells by pulse
zoledronate exposure results in higher purity, numbers,
and quality of Vγ2Vδ2 T cells. The Vγ2Vδ2 T cells were
significantly more effective at mediating tumor immun-
ity in adoptive immunotherapy halting tumor growth
and decreasing tumor volume by 50% compared with
Vγ2Vδ2 T cells expanded by continuous zoledronate
exposure. Pulse zoledronate stimulation similarly im-
proved expansion of Vγ2Vδ2 T cells with IL-15. How-
ever, adoptive transfer of Vγ2Vδ2 T cells expanded with
IL-15 did not result in improved tumor immunity com-
pared to those expanded with IL-2.
Methods
Reagents
FITC-conjugated anti-human Vδ2 TCR (clone B6),
allophycocyanin-Cy7-conjugated anti-human CD3 (clone
SK7), FITC-conjugated anti-human TCR γδ (clone B1),
allophycocyanin-conjugated anti-human Vδ2 mAb (clone
B6), FITC- and PE-conjugated anti-human CD3 (clone
SP34), PerCP-Cy5.5 anti-human CD27 (clone MT271),
PE-Cy7-conjugated anti-human CD28 (clone CD28.2),
allophycocyanin-conjugated anti-human CD45RO (clone
UCHL1), PE-conjugated anti-human IL-21 (clone 3A3-
N2.1), PE-Cy5- and PE-conjugated anti-human CD107a
(clone H4A3), PE-conjugated anti-human IFN-γ (clone
4S.B3), and allophycocyanin-conjugated anti-human TNF-
α (clone MAB11) antibodies were purchased from BD
Biosciences (San Jose, CA). PE-conjugated anti-human
CD107a (clone H4A3), PerCP-Cy5.5-conjugated anti-
human IL-17 (clone eBio64DEC17), PE-conjugated
anti-human granzyme B (clone GB11), PE-conjugated
anti-human IL-4 (clone 4D9-8), and PE-conjugated
anti-human perforin (clone dG9) antibodies were
purchased from eBioscience (San Diego, CA). The
PE-conjugated anti-human IL-22 (clone 142928) anti-
body was purchased from R&D Systems (Minneapolis,
MN). Live cells were distinguished from dead cells by
staining with Hoechst 33258 or Live/Dead Blue (Thermo-
Fisher Scientific, Waltham, MA). Pamidronate (3 mg/ml)
was from Hospira, Inc. (Lake Forest, IL). Zoledronate was
provided by Dr. Eric Oldfield.
Ex vivo expansion of Vγ2Vδ2 T cells
PBMC from random healthy adult donors were obtained
by density centrifugation over Ficoll-Hypaque (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ) of either
random donor leukopaks (12 donors) (obtained from
AllCells, LLC., Alameda, CA or the Blood Donor Center
at the Dana-Farber Cancer Institute) or fresh blood
(donors 2, 3, 4, and 6). Leukopak PBMCs were frozen
prior to use whereas PBMC isolated from blood were used
directly. Note, we primarily used frozen leukopak PBMC
because this is the source of cells for most of the clinical
trials assessing the adoptive transfer of Vγ2Vδ2 T cells.
For most experiments, complete media (C-Media) was
used and was prepared with 500 ml RPMI 1640 supple-
mented with 10 ml of 1 M HEPES, 5 ml of 200 mM L-
glutamine, 5 ml of 100 mM sodium pyruvate, 5 ml of
50× MEM essential amino acids, 5 ml of 100× MEM
non-essential amino acids, 0.5 ml of 55 mM 2-
mercaptoethanol, 5 ml of 1000× penicillin/streptomycin
(optional), 0.5 ml of 10 mg/ml gentamicin (optional) (all
from Thermo Fisher Scientific, Waltham, MA), and
50 ml of fetal calf serum (FCS) and 12 ml of human AB+
serum (Gemini Bio-Products, West Sacramento, CA).
The media was adjusted to pH ~7.2 with 1.5-2.0 ml of
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2 M NaOH prepared with cell culture grade H2O and
filtered through a 0.2 μm nylon filtration unit. The FCS
was prescreened for support of T cell growth by asses-
sing cloning efficiency of human T cell lines or clones.
Human serum was prescreened by assessing support of
Vγ2Vδ2 T cell expansion in response to HMBPP. A
detailed protocol for this media is available on request.
OpTmizerTM media was purchased from Thermo Fisher
Scientific and used as directed. IL-2 was used at 1000 IU
(60 ng/ml or 4 nM) (either as aldesleukin (Chiron,
Emeryville, CA) or teceleukin (Roche Holding AG, Basel,
Switzerland)). IL-15 was used at 50–100 ng/ml (Pepro-
Tech, Inc., Rocky Hill, NJ). For T cell functional assays
and for culturing tumor cells, human serum was omitted
and 12 ml of FCS was substituted.
For expansions performed in 96-well plates, 1 × 105
PBMCs in 100 μl media was added to equal volumes of
media containing varying concentrations of 2× HMBPP
or zoledronate per round bottom well. For pulsing, after
4 h the plates were centrifuged and the media with zole-
dronate removed by flicking and blotting any remaining
media on a sterile pad. The cells were washed three
times and then 200 μl media was added. On day 3,
100 μl media was removed and replaced with media
containing 2× IL-2 or IL-15. For expansions performed
in 24-well plates or 75 cm2 flasks, PMBC were sus-
pended at 1 × 106 cells/ml in C-media lacking IL-2 with
the indicated amount of HMBPP or zoledronate. For
pulsing, the cells were incubated for 4 h at 37 °C and 5%
CO2, washed three times with PBS, and resuspended in
C-Media without zoledronate for use. On day 3, 50% of
the media was removed and replaced with media con-
taining 2× IL-2 or IL-15. PBMC were incubated for 14 d
at 37 °C and 5% CO2. Cell growth was monitored by
microscope examination and media color. Every 2–4 d,
50% of the media was changed for fresh C-Media (con-
taining IL-2 or IL-15 but without zoledronate or
HMBPP) and the cells were split 1:2 depending on cell
density. On day 14, the cells were harvested, washed
twice with PBS, and counted. Levels of γδ and Vγ2Vδ2
T cells and their differentiation state were assessed by
flow cytometric analysis.
Purification of Vγ2Vδ2 T cells
After ex vivo expansion for 14 d, Vγ2Vδ2 T cells were
positively purified using antibody-coated magnetic beads
(MACS, Miltenyi Biotec, San Diego, CA). Expanded cells
were washed once with PBS, counted, and then 1 × 107
cells were resuspended in 0.1 ml buffer, and reacted with
10 μl of allophycocyanin-conjugated anti-human Vδ2
mAb (clone B6) for 10 min on ice in the dark in ten
2 ml microcentrofuge tubes. Cells were then washed
twice with purification buffer, resuspended in 80 μl of
buffer, and 20 μl of anti-allophycocyanin magnetic beads
added. The cells and beads were incubated on ice for
15 min and then washed twice. 1 × 108 cells were resus-
pended in 500 μl of purification buffer, and then loaded
onto an LS column for positive selection. Retained Vδ2
T cells were washed on the column three times with
3 ml of buffer, removed from the magnetic field, and
then eluted, washed, and tested either in vitro for their
functional activity or in vivo for their anti-tumor im-
munity. Cell purify was evaluated by flow cytometry and
the Vγ2Vδ2 T cells used were at least 95% Vδ2 cells (most
preparations were > 98% and examples of the purity of the
Vγ2Vδ2 T cells are shown in Additional file 1: Figure S1).
Note that an anti-Vδ2 mAb was used to determine
Vγ2Vδ2 T cells after expansion by HMBPP or zoledronate
because only γδ T cells expressing Vγ2Vδ2 TCRs respond
and expand to prenyl pyrophosphates and aminobispho-
sphonates [14, 49, 50]. After expansion, all Vδ2 chains are
paired with Vγ2 chains because in adult PBMC, a Vδ2
chain is almost always paired with a Vγ2 chain. The
converse is not always the case because Vγ2 chains
sometimes pair with Vδ1 chains.
CD107a and intracellular cytotoxic protein and cytokine
expression after stimulation of expanded Vγ2Vδ2 T cells
To assess the functional activity of Vγ2Vδ2 T cells ex-
panded under different conditions, the surface mobilization
of CD107a, cytotoxic protein levels, and cytokine levels
were measured. CD107a surface mobilization was per-
formed as previously described [7, 51]. After 14 d of expan-
sion, Vγ2Vδ2 T cells were either washed twice for use
(unpurified cells) or purified using antibody-coated mag-
netic beads as described above. Human PC-3 prostate
cancer cells (ATCC, Manassas, VA) were thawed and cul-
tured in F12 media for 2 d. The PC-3 cells were treated
overnight by culture with 200 μM pamidronate. The
pamidronate-treated PC-3 cancer cells were washed and
used to stimulate unpurified and purified Vγ2Vδ2 T cells.
Daudi (ATCC, Manassas, VA) and Raji Burkitt’s lymphoma
cell lines were cultured in RPMI 1640, washed, and directly
used to stimulate Vγ2Vδ2 T cells. For unpurified Vγ2Vδ2
T cells, E:T ratios were based on the number of Vγ2Vδ2 T
cells. Cells were mixed at different E:T ratios (1:1 to 100:1)
and cultured in C-media at 37 °C with PE-Cy5- or PE-
conjugated anti-CD107a mAbs in the presence of monen-
sin at 4 μl of GolgiStop (BD Biosciences) per 6 ml media.
After 4 h, the cells were harvested, washed, stained with
allophycocyanin-Cy7- or PE-anti-CD3 and FITC-anti-Vδ2
mAbs, and then staining was assessed by flow cytometry.
To measure cytokine production and cytotoxic protein
capabilities, unpurified or purified Vγ2Vδ2 T cells were
stimulated with pamidronate-treated PC-3 cancer cells for
4 h in the presence of monensin at 4 μl of GolgiStop (BD
Biosciences) per 6 ml media. Alternatively, purified
Vγ2Vδ2 T cells were stimulated with ionomycin (2 μg/ml)
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and PMA (50 ng/ml) (both from Sigma-Aldrich, St. Louis,
MO) for 4–6 h in the presence of monensin at 4 μl of
GolgiStop (BD Biosciences) per 6 ml media. For flow cyto-
metric analysis, PBMC were first stained with Live/Dead
Blue (Invitrogen), to exclude dead cells followed by
staining with allophycocyanin-Cy7-conjugated anti-
CD3 and FITC-conjugated anti-Vδ2 mAbs. The cells
were then washed, fixed, and permeabilized using the
Cytofix/Cytoperm Kit (BD Biosciences) and then intra-
cellularly stained with either PE-conjugated anti-IFN-γ,
anti-granzyme B, anti-perforin, anti-IL-22, anti-IL-4, allop
hycocyanin-conjugated anti-TNF-α, or PerCP-Cy5.5-con-
jugated anti-IL-17a mAbs. Cytokine and cytotoxic protein
levels of Vδ2 T cells were assessed by flow cytometry.
Fluorometric assessment of T lymphocyte antigen
specific lysis
Cytotoxicity of expanded Vγ2Vδ2 T cells against tumor
cells was determined using fluorometric assessment of T
lymphocyte antigen specific lysis (FATAL) [52]. Briefly,
PC-3 prostate cancer cells were treated with 200 μM of
pamidronate overnight. Pamidronate-treated PC-3
cells were then stained with PKH-26 using a kit
(Sigma-Aldrich, St. Louis, MO). PC-3 cells were
washed, resuspended in 75 μl of diluent C, mixed with
75 μl of PKH-26 dye (4 × 10−6 M), and incubated for
4 min at room temperature. 150 μl of FCS was then
added to stop the staining reaction, and the cells
washed once in 10 ml of PBS. The cells were then re-
suspended in 75 μl PBS and mixed with 75 μl of 5 μM
carboxyfluorescein diacetate succinimidyl ester (CFSE)
dye (Vybrnat CFDA SE Cell Racer Kit, ThermoFisher,
Molecular Probes, Eugene, OR). 150 μl of FCS was im-
mediately added to stop the staining reaction. The cells
were washed twice with PBS and resuspended for use.
5 × 103 PKH-26/CFSE stained PC-3 cells were then
incubated for 5 h with varying numbers of purified
Vγ2Vδ2 T cells that had been expanded either by con-
tinuous or pulse stimulation. Tumor specific killing by
Vγ2Vδ2 T cells was then assessed by flow cytometry.
Target % survival was calculated as (mean CFSEhi per-
cent of test well/ mean CFSEhi percent of spontaneous
release) × 100. Specific lysis was calculated as 100 − %
survival. Lytic units per 1 × 107 T cells were calculated
for 20% lysis as 107 / ((5 × 103) × x) where x = E:T ratio
corresponding to 20% specific target cell lysis [53].
Human tumor xenograft and adoptive transfer of purified
Vγ2Vδ2 T cells into immunodeficient mice
To assess the anti-tumor activity of adoptively trans-
ferred Vγ2Vδ2 T cells, human PC-3 cancer cells were
xenotransplanted into immunodeficient mice using a
model developed by the Scotet laboratory [54] except
that treatment was started one day earlier (day 13 rather
than day 14), only purified Vγ2Vδ2 T cells grown for 14
d were used, and treatment was for five weeks rather
than four. Note that for these experiments, human
Vγ2Vδ2 T cells allogeneic to the tumor were used.
Unlike αβ T cells, Vγ2Vδ2 T cells do not exhibit allor-
eactivity [55]. Therefore, by using purified Vγ2Vδ2 T
cells all potential alloreactive responses were avoided.
Female, five-week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ (NSG) mice were purchased from the Jackson La-
boratory (Bar Harbor, ME) and used at 6 weeks of age.
For tumor xenotransplantation, 1 × 107 human PC-3
cancer cells were suspended in 200 μl of sterile PBS and
s.c. inoculated into the right flank of NSG mice on day
0. Each treatment group consisted of 8 mice. On day 13
(when tumor diameter had reached > 5 mm), mice were
injected i.v. with pamidronate (50 μg/kg). The mice
weighed 17 to 19 grams and therefore received 0.85 to
0.95 μg of pamidronate. This was followed on day 14
with the i.v. injection of 1 × 106 purified Vγ2Vδ2 T cells
that had been expanded either by continuous or pulse
zoledronate stimulation with IL-2 or IL-15. For each
treatment, Vγ2Vδ2 T cells were purified on day 14 from
freshly expanded Vγ2Vδ2 T cells derived from frozen
leukopak PBMC from the same donor. These treatments
were repeated weekly until week 6. Control mice re-
ceived only pamidronate treatments. Note that in this
model, pamidronate by itself only minimally inhibits the
growth of PC-3 tumors [54]. Tumor size was assessed
once weekly by external measurement of the longitudinal
and transverse tumor diameter using a digital vernier cali-
per. Tumor volume was calculated using the modified
ellipsoidal formula where tumor volume (mm3) = (y × x2) /
2, where “y” is the longitudinal length and “x” is the trans-
verse width. All experiments involving animals, including
their housing and care in pathogen–free conditions.
Statistical analyses
For statistical analyses, either the unpaired t test or the
nonparametric Mann–Whitney U test was used as indi-
cated with p < 0.05 considered statistically significant.
Statistical analyses were done in Prism version 6.0 g
(GraphPad Software, La Jolla, CA).
Results
Pulse zoledronate stimulation improves the purity and
number of expanded Vγ2Vδ2 T cells
In our previous study, we found that continuous aminobi-
sphosphonate exposure during culture inhibits the prolifer-
ation of Vγ2Vδ2 T cells as well as other γδ and αβ T cells
[15]. This toxicity results in the suboptimal expansion of
Vγ2Vδ2 T cells over a narrow aminobisphosphonate con-
centration range whereas pulse exposure results in larger
expansions over a wide concentration range [15]. However,
in this previous study, the numbers of Vγ2Vδ2 T cells were
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not determined and only a limited number of donors were
used. Also, the activity of Vγ2Vδ2 T cells against tumor
cells was not compared for Vγ2Vδ2 T cells grown under
the different conditions. Thus, to assess the effect on
Vγ2Vδ2 T cells of pulse versus continuous exposure to
zoledronate, PBMC were cultured with varying concentra-
tions of zoledronate continuously or for 4 h. On day 14,
Vγ2Vδ2 T cells were then measured and their tumor
immunity evaluated. Note that PBMC continuously
exposed to zoledronate had half of their media changed
on day 3 and every 2–4 d thereafter. Thus the full
concentration of zoledronate was only present for the
first 3 d of culture.
Most donors responded to continuous zoledronate
exposure with the highest levels of Vγ2Vδ2 T cells
between 3–10 μM (Fig. 1a, right panels, open circles).
Fig. 1 Expanding Vγ2Vδ2 T cells by pulse zoledronate stimulation with IL-2 increased their purity and number compared with continuous stimulation.
a Expansion of Vγ2Vδ2 T cells in response to varying doses of HMBPP and zoledronate with IL-2. Human Vγ2Vδ2 T cells were expanded ex vivo from
PBMC by exposure to HMBPP (left panels) or zoledronate (right panels). Human PBMC were cultured in 96-well plates either continuously with varying
starting concentrations of HMBPP or zoledronate (open circles) or pulsed with zoledronate for 4 h (closed circles) followed by washing twice. IL-2 was
added to 1000 IU on day 3. Thereafter, media was changed every 2–3 d depending on cell growth. On day 14, Vγ2Vδ2 T cell numbers were
determined by flow cytometric analysis. b, c Numbers of Vδ2 T cells after 14 d expansion under the indicated conditions with IL-2 for triplicate
cultures in either 96-well plates (b) (results for eight donors) or 24-well plates (c) (results for nine donors). PBMC were cultured for 14 d in the
presence of IL-2 at 1 × 105 cells/well for 96-well plates or 1 × 106 cells/well for 24-well plates. **p < 0.01 compared to 10 μM zoledronate
continuous stimulation using the Mann–Whitney U test. Mean and standard deviation is shown. d Comparison of the purity (left panel) and
number (right panel) of Vδ2 T cells expanded by continuous (10 μM) or pulse (100 μM) stimulation with zoledronate with IL-2 in 24-well plates.
Each line connects the results for an individual donor. Results for nine donors from (c)
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For six of the eight donors, higher zoledronate concen-
trations greatly decreased responsiveness although 2
donors (Donors 4 and 7) responded even at higher con-
centrations. In contrast, all eight donors responded to
pulse zoledronate exposure similarly over a 30-100-fold
range from ~10-100 μM (Fig. 1a, right panels, closed
circles). HMBPP shows no toxic effect on Vγ2Vδ2 T
cells even at high concentrations (Fig. 1a, left panels).
To assess Vγ2Vδ2 T cell numbers after expansion, zole-
dronate at 1 μM and 10 μM was chosen for continuous
stimulation of PBMC to be consistent with clinical trials.
Pulse stimulation with zoledronate was done at 100 μM.
Despite achieving similar levels of purity in many cases
(Fig. 1a, right panels), the number of Vγ2Vδ2 T cells at day
14 expanded by pulse stimulation with zoledronate
(100 μM) in 96-well plates averaged 8.6-fold greater than
the number of cells derived by continuous stimulation with
zoledronate (10 μM) (Fig. 1b, p < 0.01). Increases in the
number of Vγ2Vδ2 T cells were also noted when PBMC
were cultured in 24-well plates with an average of 1.9-fold
greater number of cells (Fig. 1c, p < 0.01). All donors exhib-
ited increases in purity (mean Vγ2Vδ2 T cells were 58.8%
for continuous stimulation versus 80.4% for pulse stimula-
tion, Fig. 1d, left panel) and in Vγ2Vδ2 T cell numbers
(mean cell numbers were 8.5 × 106 cells for continuous
stimulation versus 16.5 × 106 cells for pulse stimulation,
Fig. 1d, right panel). Increases in cell numbers between
donors ranged from 1.4- to 5.4-fold. Thus, exposure of
PBMC to zoledronate for a short 4 h period resulted in
increased purity and yield of Vγ2Vδ2 T cells compared
with continuous zoledronate exposure. These levels are
comparable to those achieved with exposure to HMBPP.
However, HMBPP has not been used for clinical studies
due to a lack of availability of pharmaceutical grade
HMBPP and possible patent infringement issues.
Vγ2Vδ2 T cells expanded by pulse zoledronate
stimulation exhibit increased degranulation and perforin
expression compared with those expanded by continuous
stimulation when stimulated by pamidronate-treated PC-3
cancer cells or Daudi Burkitt’s lymphoma cells
To assess the function of expanded Vγ2Vδ2 T cells
derived using pulse stimulation, their surface expression
of CD107a and intracellular expression of cytotoxic pro-
teins and cytokines were measured in response to TCR
stimuli. CD107a (LAMP-1) is a lysosomal membrane
protein that is mobilized to the surface when cytotoxic T
and NK cells degranulate for killing [51, 56, 57]. When
cultured with pamidronate-treated PC-3 prostate cancer
cells that have high intracellular levels of IPP, a higher
proportion of Vγ2Vδ2 T cells expanded by pulse stimula-
tion expressed CD107a compared with Vγ2Vδ2 cells
expanded by continuous stimulation (50.9% versus 38.2%
for purified Vγ2Vδ2 T cells, Fig. 2a, p < 0.05). Similar
Fig. 2 Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation with IL-2 exhibit slightly increased degranulation and expression of granzyme B
and perforin compared with those expanded by continuous stimulation when exposed to pamidronate-treated PC-3 cancer cells. Human PBMC
were cultured either continuously with zoledronate (5 μM) or pulsed with zoledronate (100 μM) for 4 h and then washed twice before culture
with IL-2 (1000 IU/ml). After 14 d, expanded Vγ2Vδ2 T cells were purified by positive selection or left unpurified. PC-3 cancer cells were treated
overnight with pamidronate (200 μM) and then washed. Pamidronate-treated PC-3 cells were incubated with unpurified or purified Vγ2Vδ2 T cells
for 4 h in duplicate samples followed by surface and intracellular mAb staining. CD107a, IFN-γ, granzyme B, perforin, IL-17A, and IL-21 levels on or
in Vγ2Vδ2 T cells were assessed by flow cytometric analysis. Mean ± SD is shown. Representative of two experiments. *p < 0.05 compared to
10 μM zoledronate continuous stimulation using the unpaired t-test
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results were noted with stimulatory Daudi lymphoma cells
with a higher proportion of Vγ2Vδ2 T cells expanded by
pulse stimulation expressing CD107a than Vγ2Vδ2 cells
expanded by continuous stimulation (31.9% versus 19.5%,
p = 0.0058, Additional file 1: Figure S2a, b).
Consistent with their high level of CD107a, Vγ2Vδ2
T cells expanded by pulse stimulation had signifi-
cantly higher proportions expressing perforin com-
pared with Vγ2Vδ2 T cells derived with continuous
stimulation. Other cytotoxic proteins and cytokines
were expressed at similar levels with Vγ2Vδ2 T cells
from both conditions producing high levels of IFN-γ
and granzyme B. There were low proportions of
Vγ2Vδ2 T cells producing IL-17A (as observed previ-
ously in Ref. [58]) and IL-21 (Fig. 2b-f ). IL-10 was
not produced by expanded Vγ2Vδ2 T cells (data not
shown). Activation by the mitogen, ionomycin, with
PMA, stimulated IFN-γ and granzyme B to similar
very high proportions of Vγ2Vδ2 T cells expanded
using either condition (Additional file 1: Figure S2c).
Thus, a significantly higher proportion of Vγ2Vδ2 T
cells degranulated in response to pamidronate-treated
PC-3 prostate cancer cells and Daudi lymphoma cells
when derived using pulse stimulation compared with
those derived by continuous stimulation.
Cytotoxicity of Vγ2Vδ2 T cells expanded by pulse
zoledronate stimulation against pamidronate-treated PC-3
prostate cancer cells
Cytotoxicity of Vγ2Vδ2 T cells for tumor cells was
assessed by fluorometric measurement of tumor cell
lysis. In this assay, tumor cells are stained with fluores-
cent dyes to allow their identification and to evaluate
their viability after incubation with cytotoxic T or NK
cells [52]. For our experiments, purified Vγ2Vδ2 T cells
expanded using either pulse or continuous zoledronate
stimulation were mixed at different E:T ratios (1:1 to
100:1) with pamidronate-treated PC-3 tumor cells.
Specific killing of PC-3 cells was then assessed by flow
cytometric analysis. Vγ2Vδ2 T cells expanded by pulse
stimulation killed PC-3 prostate cancer cells more effi-
ciently than those expanded by continuous zoledronate
stimulation. Vγ2Vδ2 T cells expanded by pulse stimula-
tion had 155.5 lytic units (for 20% target cell lysis per
1 × 107 T cells) compared with 61.3 lytic units (2.5-fold
lower) for Vγ2Vδ2 T cells expanded by continuous
stimulation (Fig. 3a, b). Thus, consistent with the
CD107a expression results, Vγ2Vδ2 T cells expanded by
pulse stimulation exhibited higher levels of cytotoxicity
for tumor cells than those expanded using continuous
zoledronate stimulation.
Fig. 3 Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation exhibit similar cytotoxicity against pamidronate-treated PC-3 cancer cells compared
with Vγ2Vδ2 T cells expanded by continuous stimulation. Vγ2Vδ2 T cells were expanded as described in Fig. 2. Vγ2Vδ2 T cells expanded by continuous
or by pulse zoledronate stimulation were then purified for use. PC-3 cancer cells were treated overnight with pamidronate (200 μM) and then washed
twice. To assess cytotoxicity, the FATAL assay was used. Pamidronate-treated PC-3 cells were stained with PHK-26 and CFSE and incubated with
purified Vγ2Vδ2 T cells for 5 h at various E:T ratios in duplicate. Cells were then fixed with 1% paraformaldehyde followed by flow cytometric analysis.
a CFSE levels of PC-3 prostate cancer cells incubated with varying numbers of purified Vγ2Vδ2 T cells expanded by continuous or pulse zoledronate
stimulation. b Cytolytic activity of Vγ2Vδ2 T cells expanded either by continuous or pulse zoledronate stimulation against pamidronate-treated PC-3
cancer cells as determined by the FATAL assay. Representative of two experiments
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Adoptive transfer of Vγ2Vδ2 T cells expanded using pulse
zoledronate stimulation controlled PC-3 tumor growth in
NSG mice
To assess the in vivo anti-tumor activity of Vγ2Vδ2 T
cells expanded under the two conditions, a humanized
immunodeficient mouse model developed by the Scotet
laboratory was used [54]. In this model, human PC-3
prostate cancer cells are xenotransplanted into the flanks
of highly immunodeficient NSG mice followed 2 weeks
later by 4 weekly treatment with the aminobisphospho-
nate, pamidronate, and adoptively transferred Vγ2Vδ2 T
cells (schema shown in Fig. 4a). The only modifications
to their protocol that were made were that mice were
treated with pamidronate on day 13 instead of day 14
and that freshly purified Vγ2Vδ2 T cells (>98% purity,
Additional file 1: Figure S1) from 14 day cultures were
used for each adoptive transfer rather than unpurified
Vγ2Vδ2 T cells from cultures of varying ages. The use of
purified Vγ2Vδ2 T cells allowed us to directly compare
the anti-tumor activity of Vγ2Vδ2 T cells expanded under
the two conditions using identical numbers of transferred
T cells. Vγ2Vδ2 T cells were expanded from frozen leuko-
pak PBMC derived from a single donor to more closely
approximate present clinical treatment protocols.
Adoptive transfer of Vγ2Vδ2 T cells expanded under
either condition greatly slowed tumor growth with large
decreases in tumor volume (Fig. 4b) and tumor diameter
(Additional file 1: Figure S3b) compared with pamidro-
nate treatment alone. These results are identical to those
reported by Santolaria et al. [54]. Pamidronate treatment
alone had no effect on tumor growth whereas mice
treated with pamidronate followed by Vγ2Vδ2 T cells
derived using continuous zoledronate stimulation slowed
tumor growth with slight increases in tumor volume and
diameter. In contrast, tumor growth stopped in mice
treated with Vγ2Vδ2 T cells expanded using pulse
Fig. 4 Adoptive transfer of Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation in combination with pamidronate controlled PC-3 prostate
tumor growth in NSG mice. a Schema of treatment protocol used to evaluate the anti-tumor efficacy of Vγ2Vδ2 T cells. Immunodeficient NSG
mice were s.c. inoculated with human PC-3 prostate cancer cells on day 0. On day 13, pamidronate (50 μg/kg) was given i.v. On day 14, 1 × 106
purified Vγ2Vδ2 T cells expanded using either continuous or pulse zoledronate stimulation were inoculated i.v. Treatments were repeated weekly until
week 6. Longitudinal and transverse diameters of the tumors were measured weekly. b, left panel Vγ2Vδ2 T cells stimulated by pulse zoledronate
exposure exhibit significantly better anti-tumor immunity compared with those expanded by continuous zoledronate exposure. Mean PC-3 tumor
volume ± SD is shown for 7–8 mice per group treated with either pamidronate alone (open triangles), pamidronate with purified Vγ2Vδ2 T cells
derived by continuous zoledronate stimulation (open circles), or pamidronate with purified Vγ2Vδ2 T cells derived by pulse zoledronate stimulation
(closed circles). **p < 0.01, ***p < 0.001 compared with tumor volume of mice treated with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation
using the Mann–Whitney U test. Right panel, Tumor volume at week 7 of individual mice treated with pamidronate alone (open triangles), pamidronate
with Vγ2Vδ2 T cells derived by continuous zoledronate stimulation (open circles), or pamidronate with Vγ2Vδ2 T cells derived by pulse zoledronate
stimulation (closed circles). Bars represent mean values. **p < 0.01, ***p < 0.001 using the Mann–Whitney U test
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zoledronate stimulation with significantly lower tumor
volumes (Fig. 4b, p < 0.01) and tumor diameters
(Additional file 1: Figure S3b, p < 0.01) compared with
treatment with Vγ2Vδ2 T cells expanded using con-
tinuous zoledronate stimulation. Tumor volume was
reduced by 42% at week 7 (Fig. 4b, right panel) and
averaged 46% reductions for weeks 5–7. Thus, while
adoptive transfer of Vγ2Vδ2 T cells expanded under
either condition greatly slowed tumor growth, tumors
in mice treated with Vγ2Vδ2 T cells expanded using
pulse stimulation were about half the size of tumors
in mice treated with Vγ2Vδ2 T cells expanded using
continuous stimulation. This better tumor control is
consistent with the increased cytotoxicity of these
cells in vitro.
Pulse zoledronate stimulation improves the purity and
yield of Vγ2Vδ2 T cells cultured with IL-15
IL-15 is a cytokine supporting T cell growth that is
a member of the common γC cytokine family that
also includes IL-2, IL-7, and IL-21. Tumor-reactive
murine CD8 αβ T cells expanded ex vivo using IL-
15 [44, 45] or IL-7/IL-15 [46] mediate increased
tumor immunity in vivo as compared to cells grown
in IL-2. However, comparable studies have not been
reported for Vγ2Vδ2 T cells. Therefore, we assessed
whether pulse zoledronate stimulation would also
improve expansion of Vγ2Vδ2 T cells when IL-15
was used. Similar to stimulation with IL-2, Vγ2Vδ2
T cells expanded using continuous zoledronate
stimulation in 96-well plates showed maximal ex-
pansion between 1–10 μM with higher concentra-
tions greatly decreasing expansion (Fig. 5a, right
panels). In contrast, expansion of Vγ2Vδ2 T cells
using pulse zoledronate stimulation showed expan-
sion over a broader range of up to 100-fold (Donors
4 and 8). Maximal purity levels were similar be-
tween the various conditions and to levels observed
with HMBPP stimulation (except for Donor 9).
Direct comparison for individual donors showed
similar results for IL-2 and IL-15 when evaluated in
parallel (Additional file 1: Figure S4).
Both the purity and number of Vγ2Vδ2 T cells was
higher with pulse zoledronate stimulation compared
with continuous stimulation with levels similar to
those observed with HMBPP (Fig. 5b). All donors
except one, exhibited increases in purity (Fig. 5c, left
panel) and in Vγ2Vδ2 T cell numbers (Fig. 5c, right
panel) with pulse zoledronate stimulation. Increases
in cell numbers ranged from 1.1- to 4.8-fold, aver-
aging 2.4-fold for the 8 donors. These findings were
consistent with those observed with Vγ2Vδ2 T cell
expansion with IL-2.
IL-15 preserves higher proportions of early/central
memory subsets of Vγ2Vδ2 T cells
Previous studies with αβ T cells have shown that IL-15
specifically sustains the early/central memory subsets of
CD8 αβ T cells [59, 60] and in combination with IL-7
maintain stem αβ T cells [61]. Early/central memory CD8
αβ Tcells confer stronger anti-tumor immunity upon adop-
tive immunotherapy compared with late/effector T cells in
mouse models [47, 62]. To determine the effect of IL-15 on
Vγ2Vδ2 T cells, we compared the proportion of memory
subsets in the presence of either IL-2 or IL-15 following
zoledronate or HMBPP stimulation. CD28 and CD27 were
used as phenotypic markers for different Vγ2Vδ2 T cell
memory subsets because these receptors distinguish early/
central memory (CD28+ CD27+/−) from intermediate
(CD28− CD27+) or late/effector memory (CD28− CD27−)
cells (data not shown and [63]). The gating strategy is
shown for Vγ2Vδ2 T cells from PBMC (Fig. 6a). Note that
in adults, almost all Vγ2Vδ2 T cells are memory cells with
the naive population being very small (<2%).
When Vγ2Vδ2 T cells were expanded by zoledronate
or by HMBPP stimulation in the presence of IL-15, the
majority of Vγ2Vδ2 T cells were early/central memory
cells (colored green (CD28+ CD27+) or yellow (CD28+
CD27−) in Fig. 6b, right panels) whereas the majority of
Vγ2Vδ2 T cells expanded in the presence of IL-2 were
late/effector memory cells (colored red (CD28− CD27−)
or blue (CD28− CD27+) in Fig. 6b, left panels). There
were significantly more early/central memory T cells
when Vγ2Vδ2 T cells were expanded by pulse zoledro-
nate stimulation in IL-15 and more late/effector memory
T cells with pulse zoledronate stimulation in IL-2 (Fig. 6c,
right panel). Similar results were noted with continuous
stimulation (Fig. 6c, left panel). Therefore, IL-15 main-
tained a higher proportion of early/central memory
subsets of Vγ2Vδ2 T cells than IL-2.
Vγ2Vδ2 T cells expanded using pulse zoledronate
stimulation with IL-15 express CD107a, cytotoxic proteins,
and cytokines in similar proportions to those expanded
with IL-2
To assess the effect of IL-15 on Vγ2Vδ2 T cell function,
the expression of CD107a, cytotoxic proteins, and cyto-
kines were measured in Vγ2Vδ2 T cells expanded by
pulse zoledronate stimulation with IL-15 in comparison
to Vγ2Vδ2 T cells expanded with IL-2. PC-3 cancer cells
were treated with pamidronate to increase intracellular
IPP levels. The treated PC-3 cells were then used to
stimulate purified Vγ2Vδ2 T cells that were derived
using pulse zoledronate stimulation with either IL-2 or
IL-15. CD107a, granzyme B, perforin, IFN-γ, TNF-α, and
IL-4 expression was then assessed by flow cytometry. No
significant differences were noted in the proportion of
Vγ2Vδ2 T cells expressing CD107a, granzyme B,
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perforin, IFN-γ, and TNF-α between Vγ2Vδ2 T cells
expanded with IL-15 to those expanded with IL-2
(Additional file 1: Figure S5). There were somewhat
higher proportions of Vγ2Vδ2 T cells producing IL-4
when expanded with IL-15 but these cells constituted
a small population (<6%) and are of uncertain signifi-
cance in vivo. Thus, Vγ2Vδ2 T cells expanded with
IL-15 have similar functional capabilities to those
expanded with IL-2.
Adoptive transfer of Vγ2Vδ2 T cells expanded using pulse
stimulation with IL-15 controlled PC-3 tumor growth in
NSG mice similarly to Vγ2Vδ2 T cells expanded with IL-2
To assess the effect of IL-15 on anti-tumor activity,
Vγ2Vδ2 T cells expanded using pulse zoledronate stimu-
lation with either IL-15 or IL-2 were adoptively trans-
ferred into NSG mice bearing PC-3 prostate tumors
(Fig. 7a). Both Vγ2Vδ2 T cells expanded with IL-15 or
with IL-2 efficiently controlled PC-3 tumors stopping
Fig. 5 Expanding Vγ2Vδ2 T cells by pulse zoledronate stimulation with IL-15 increased their purity and numbers compared with continuous
stimulation. a Expansion of Vγ2Vδ2 T cells in response to varying doses of HMBPP and zoledronate with IL-15. Human Vγ2Vδ2 T cells were
expanded ex vivo from PBMC by exposure to HMBPP (left panels) or zoledronate (right panels). Human PBMC were cultured in 96-well plates
either continuously with varying starting concentrations of HMBPP or zoledronate (open circles) or pulsed with varying concentrations of
zoledronate for 4 h (closed circles) followed by washing twice. IL-15 was added to 100 ng/ml on day 3. Thereafter, media was changed every 2–3
d depending on cell growth. On day 14, Vγ2Vδ2 T cell numbers were determined by flow cytometric analysis. Results for 8 donors are shown. b,
upper panel Purity of Vδ2 T cells under the indicated conditions with IL-15 (100 ng/ml) after 14-day culture in 24-well plates. Each point represents
one donor (n = 8). ** p = 0.003, Mann–Whitney U test. Lower panel, Number of Vδ2 T cells under the indicated conditions with IL-15 (100 ng/ml)
after 14-day culture in 24-well plates. Each point represents one donor (n = 8). ** p = 0.007, Mann–Whitney U test. c Comparison of the purity
(left panel) and number (right panel) of Vδ2 T cells expanded by continuous (10 μM) or pulse (100 μM) stimulation with zoledronate with IL-15 in
24-well plates. Each line connects the results for an individual donor from (b)
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their growth but not eliminating the tumors. There were
no significant differences in tumor volume (Fig. 7b) or
tumor diameter (Additional file 1: Figure S6) when
Vγ2Vδ2 T cells expanded with IL-15 (open circles) were
compared to those expanded with IL-2 (closed circles).
Moreover, at week 8, two weeks after adoptive transfer
Fig. 6 IL-15 sustained higher proportions of early/central memory subsets among expanded Vγ2Vδ2 T cells compared to IL-2. a Gating strategy
for delineating memory subsets of Vγ2Vδ2 T cells from blood. Memory status of Vγ2Vδ2 T cells was assessed by expression of CD27 and CD28.
CD28+/CD27+ and CD28+/CD27− cells are early/central memory cells that express CD45RO. CD28−/CD27+ cells are intermediate memory cells.
CD28−/CD27− cells are late memory cells that express CD45RA. b Proportions of human Vγ2Vδ2 T cell memory subsets after expansion with the
indicated concentrations of HMBPP or zoledronate by continuous and pulse stimulation and in the presence of IL-2 (left panels) or IL-15 (right panels) for
14 days. Data for four donors is shown. c, left panel Comparison of the proportion of memory subsets of Vγ2Vδ2 T cells expanded by continuous
zoledronate stimulation (10 μM) with IL-2 or IL-15. Mean ± SEM for 4 individuals. Right panel, Comparison of the proportion of memory subsets of Vγ2Vδ2
T cells expanded by pulse zoledronate stimulation (100 μM) with IL-2 or IL-15. Mean ± SEM for 4 individuals. ** p< 0.01 using the unpaired t-test
Nada et al. Journal for ImmunoTherapy of Cancer  (2017) 5:9 Page 12 of 23
of Vγ2Vδ2 T cells had stopped, tumor growth resumed
in both groups without significant differences albeit at a
slower rate of growth than PC-3 tumors treated with
pamidronate alone. Therefore, expansion of Vγ2Vδ2 T
cells with IL-15 did not improve immunity against pros-
tate tumors in our humanized mouse model. This result
is consistent with the absence of significant differences
in the in vitro function of Vγ2Vδ2 T cells expanded with
IL-15 compared to those expanded with IL-2.
Vγ2Vδ2 T cells stimulated by pulse zoledronate expand
to similar levels using OpTmizer™ media manufactured
under cGMP and with large scale cultures
To determine if pulse zoledronate stimulation could
improve current practices in clinical trials, we examined
whether similar results could be obtained using com-
mercial media used for T cell expansions that is pro-
duced under current good manufacturing practices
(cGMP) and with larger scale expansions. To meet regu-
latory requirements, culture media used for clinical trials
must meet cGMP standards. Therefore, we compared
the enriched RPMI 1640 media used in our experiments
(termed C-media) with OpTmizer™ media, a media meet-
ing cGMP standards. Expansion of Vγ2Vδ2 T cells in
OpTmizer™ media (open bars) resulted in comparable
levels of Vγ2Vδ2 T cell purity (Fig. 8a) and numbers
(Fig. 8b) to those achieved using C-media (solid bars).
Consistent with experiments using C-media, expansion of
Vγ2Vδ2 T cells in OpTmizer™ media using pulse zoledro-
nate stimulation resulted in higher purity (71% vs. 42%
Vγ2Vδ2 T cells) and cell numbers (19.0 × 106 versus 8.6 ×
106 Vγ2Vδ2 T cells, 2.2-fold higher) compared with
expansion using continuous stimulation (Fig. 8a, b).
Similar increases in cell numbers were noted with lar-
ger scale expansions. Pulse zoledronate stimulation of
thawed leukopak PBMC in flasks resulted in an 858-fold
increase in Vγ2Vδ2 T cell numbers by day 14 (1.58 × 105
cells increasing to 1.35 × 108 cells, Fig. 8c). This expan-
sion was 1.9-fold higher than that achieved by continu-
ous zoledronate stimulation. Consistent with our
experiments in 24-well plates, expansion of Vγ2Vδ2 T
cells using pulse zoledronate stimulation with IL-2 in
Fig. 7 Adoptive transfer of Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation with IL-15 in combination with pamidronate controlled
PC-3 prostate tumor growth in NSG mice similarly to Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation with IL-2. a Schema of treatment
protocol used to evaluate the anti-tumor efficacy of Vγ2Vδ2 T cells. Immunodeficient NSG mice were s.c. inoculated with human PC-3 prostate cancer
cells on day 0. On day 13, pamidronate (50 μg/kg) was given i.v. On day 14, 1 × 106 purified Vγ2Vδ2 T cells expanded using pulse zoledronate
stimulation with either IL-15 or IL-2 were inoculated i.v. Treatments were repeated weekly until week 6. Longitudinal and transverse diameters of the
tumors were measured once weekly until week 9. b, left panel Vγ2Vδ2 T cells stimulated by pulse zoledronate exposure with IL-15 showed similar
anti-tumor immunity compared with those expanded with IL-2. Mean PC-3 tumor volume ± SD is shown for 7–8 mice per group treated with either
pamidronate alone (open triangles), pamidronate with purified Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-15 (open circles), or
pamidronate with purified Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 (closed circles). ***p < 0.001 compared with mean tumor
volume of mice treated with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 using the Mann–Whitney U test. Right panel, Tumor
volume at week 7 of individual mice treated with pamidronate alone (open triangles), pamidronate with Vγ2Vδ2 T cells derived by pulse zoledronate
stimulation with IL-15 (open circles), or pamidronate with Vγ2Vδ2 T cells derived by pulse zoledronate stimulation with IL-2 (closed circles). Bars
represent mean values. ***p < 0.001 using the Mann–Whitney U test
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flasks gave similar cell numbers when IL-15 was used
(774-fold with IL-2 versus 738-fold with IL-15, Fig. 8d).
These results demonstrate that pulse zoledronate
stimulation resulted in increased Vγ2Vδ2 T cell purity
and numbers with cGMP media and larger scale
expansions. Similar benefits are likely, not only for pre-
clinical in vitro studies and humanized mouse models,
but also for clinical trials employing adoptive transfer
of Vγ2Vδ2 T cells.
Discussion
Adoptive immunotherapy with Vγ2Vδ2 T cells for the
treatment of a variety of cancers has proven to be safe with
203 patients treated with few severe toxicities [64, 65].
Vγ2Vδ2 T cells can be expanded from most cancer
patients and these patients can be easily identified by test-
ing in small-scale cultures. Patients treated with Vγ2Vδ2 T
cells have had partial or complete remissions or stable
disease but most patients progress. Therefore, discovering
ways to increase the effectiveness of Vγ2Vδ2 T cell therapy
is required to realize its full potential. In this report, we
show that expanding Vγ2Vδ2 T cells by pulsing PBMC
with zoledronate increases their purity and numbers com-
pared with continuous zoledronate stimulation by decreas-
ing zoledronate toxicity to Vγ2Vδ2 T cells. Vγ2Vδ2 T cells
expanded by pulse zoledronate stimulation expressed
higher levels of perforin and a larger proportion degranu-
lated when exposed to stimulatory tumor cells. These
Vγ2Vδ2 T cells killed tumor cells more strongly with a
2.5-fold increase in cytolytic activity compared with those
expanded using continuous zoledronate stimulation. Con-
sistent with the increase in cytotoxicity, adoptive transfer
of Vγ2Vδ2 T cells expanded by pulse stimulation halted
tumor growth in vivo, reducing tumor volume by half
Fig. 8 Vγ2Vδ2 T cells stimulated by pulse zoledronate expand to similar levels using commercial cGMP grade OpTmizer™ media and with larger-scale
cultures. a, b Similar purity (a) and yield (b) of Vγ2Vδ2 T cells expanded by pulse zoledronate stimulation in cGMP grade OpTimizer™ culture media as
compared with supplemented RPMI 1640 C-media. Vγ2Vδ2 T cells from frozen leukopak PBMC were expanded by pulse zoledronate stimulation with
IL-2 for 14 d in either OpTimizer™ culture media or the supplemented RPMI 1640 C-media used in this study. Vγ2Vδ2 T cell numbers were determined
by flow cytometric analysis. Representative of two experiments. c, d Expansion of Vγ2Vδ2 T cells by pulse zoledronate culture under larger-scale
cultures yielded similar enhancements in yield as noted with small-scale cultures. For larger-scale expansion of Vγ2Vδ2 T cells, leucopak PBMCs
were stimulated by either continuous (5 μM) or pulse zoledronate (100 μM) exposure (c) as detailed in Fig. 1 with IL-2 in C-Media in 75 cm2 cell
culture flasks in triplicate cultures. For (d), Vγ2Vδ2 T cells were expanded by pulse zoledronate stimulation with either IL-2 or IL-15 in C-Media in
75 cm2 cell culture flasks in triplicate cultures. After 14 days, Vγ2Vδ2 T cell numbers were determined by flow cytometric analysis. Starting number
of Vγ2Vδ2 T cells was 0.158 × 106 for each group. Mean ± SD is shown. **p < 0.01, ***p < 0.001, ****p < 0.0001 using the unpaired t-test
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compared with equal numbers of Vγ2Vδ2 T cells
expanded by continuous stimulation. Thus, limiting
zoledronate exposure by pulsing increased both the
quantity of Vγ2Vδ2 T cells and their effectiveness in
tumor immunity.
One potential limitation of this study was our use of
normal donors. However, we and others have found that
the requirements for ex vivo expansion of Vγ2Vδ2 T
cells from cancer patients are identical to those observed
with normal donors [33, 36]. The main difference be-
tween the normal donors and patients is that a higher
proportion of cancer patients fail to respond if they have
advanced metastatic disease, are elderly, or have been
treated with chemotherapy or intravenous aminobispho-
sphonates [26, 28, 36, 66]. Previously using a modified
24 h pulse of zoledronate, the main predictor for poor
Vγ2Vδ2 T cell expansion in 18 breast cancer patients
was blood Vγ2Vδ2 T cell levels less than 1% [33]. The
83% of patients with Vγ2Vδ2 T cell levels greater than
1% had similar expansions compared with normal do-
nors regardless of the cancer stage. However, because a
higher proportion of breast cancer patients had levels
less than 1% compared with normal donors, there were
higher numbers of poor zoledronate responders. Higher
proportions of patients with metastatic cancers also had
Vγ2Vδ2 T cell levels of less than 1% and poor expan-
sions whereas those with higher levels were able to
expand normally [26]. Cancer patients with normal
blood Vγ2Vδ2 T cell levels including those with breast
cancer, prostate cancer, lung cancer, colorectal cancer, and
hepatocellular carcinoma expanded similarly to normal
donors whereas those with low levels did not [36, 67–70].
Because the requirements for expansion of Vγ2Vδ2 T cells
do not appear to differ between normal donors and cancer
patients, pulse zoledronate stimulation will give compar-
able improvements in expansion with cancer patients
whose Vγ2Vδ2 T cells are greater than 1% as we have
previously shown [33]. Pulse zoledronate stimulation
could also help improve expansion in patients with lower
Vγ2Vδ2 levels given that pulse exposure of dendritic cells
to zoledronate helped to restore Vγ2Vδ2 expansion in
tumor patients that were non- or weakly responsive to
continuous bromohydrin pyrophosphate stimulation [68].
Given that zoledronate targets the same enzyme, FDPS,
in all cells, why does limiting the period of zoledronate
exposure improve expansion of Vγ2Vδ2 T cells? This is
due to differences in the rate of uptake of zoledronate and
other aminobisphosphonates between different cell types.
Aminobisphosphonates enter cells through fluid-phase
endocytosis because they cannot passively diffuse through
cell membranes due to the negative charges on their
phosphonate moieties [71, 72]. Metabolically active cells
such as monocytes/macrophages and tumor cells have in-
creased rates of fluid-phase endocytosis compared with
resting Vγ2Vδ2 T cells. Indeed, in PBMC, only monocytes
efficiently internalize aminobisphosphonates with little or
no uptake by other cells including T cells [73]. Consistent
with this selective uptake, there are large increases in IPP/
DMAPP in monocytes after zoledronate pulsing but only
small increases in T cells [73] and monocytes are the
primary APC for aminobisphosphonate stimulation of
Vγ2Vδ2 T cells in PBMC [74]. Also, unlike resting T cells
in PBMC, highly metabolically active Vγ2Vδ2 T cell clones
do not proliferate when continuously exposed to risedro-
nate (although they do release TNF-α) presumably due to
their uptake of risedronate [15]. Risedronate also inhibits
the proliferation of αβ and other γδ T cells in response to
IL-2 or PHA [15]. Thus, pulsing of PBMC with zoledro-
nate allows for its uptake into monocytes but not into
resting Vγ2Vδ2 T cells, thereby reducing alterations in cell
signaling and direct toxicity due to ApppI.
The short period of aminobisphosphonate exposure
during the in vitro pulse period is similar to what is
observed in blood upon their intravenous administra-
tion. Aminobisphosphonate have very short half-lives in
plasma (1–2 hours) due to their renal excretion and
deposition into bone (where the half-life of alendronate
is estimated to be 10 years) [75, 76]. Even a short expos-
ure to zoledronate can result in prolonged elevations in
IPP in cells. Once bound into the dimethylallyl pyro-
phosphate site of FDPS, aminobisphosphonates function
as nearly irreversible inhibitors because IPP binding to
its site in FDPS induces a conformational change locking
them in place by closing the binding site [77]. This prop-
erty allows a brief exposure to zoledronate to effect
prolonged inhibition of FDPS enzymatic activity. For
example, increases in IPP levels are noted for 10 days
(with peak levels at day 7) in intraperitoneal monocytes
after treatment of mice with zoledronate [78] and for up
to 7 days in monocytes after in vitro exposure [79]. In
the NSG mouse model used in this report, human PC-3
tumor cells isolated from mice treated with pamidronate
stimulated CD107a expression on Vγ2Vδ2 T cells above
background for up to 5 days after treatment [54]. These
results show that given sufficient uptake, a brief expos-
ure to zoledronate can cause prolonged elevations in
cellular IPP levels.
If continuous zoledronate exposure is toxic for T cells,
why are repeated intravenous treatments with pamidro-
nate required for effective PC-3 tumor control in NSG
mice? As noted above, aminobisphosphonates given
intravenously are rapidly cleared from the blood within a
few hours. Tumor cells preferentially take up aminobi-
sphosphonates because their high rates of proliferation
and metabolic activity necessitates constant uptake of
nutrients by fluid phase endocytosis. In this respect,
aminobisphosphonates are acting similar to traditional
chemotherapeutic agents that target tumor cells because
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of their rapid proliferation by disrupting DNA synthesis,
mitosis, nucleotide synthesis, or other cellular processes.
After cell entry, aminobisphosphonates are released into
the cytoplasm where they blocks FDPS resulting in IPP/
ApppI accumulation, This accumulation can be sensed
by Vγ2Vδ2 T cells through their TCRs resulting in
activation. However, in the PC-3 NSG mouse model,
PC-3 tumor cells only remain stimulatory for up to
5 days [54]. Therefore, repeated pamidronate treatments
were required to make PC-3 cells stimulate Vγ2Vδ2 T
cells through their TCRs.
The downside of intravenous aminobisphosphonates
and prenyl pyrophosphates or their analogs is that they
anergize and/or delete Vγ2Vδ2 T cells [32, 33, 80, 81].
This is likely due to stimulation of Vγ2Vδ2 T cells by
non-professional APCs that either lack the appropriate
costimulatory signals, activate too strongly, or are in the
wrong location for the effective stimulation and main-
tenance of memory T cells. Vγ2Vδ2 T cells present
around the time of aminobisphosphonate infusion, in-
cluding those previously transferred, will be anergized
and/or deleted. To avoid this, either zoledronate therapy
is avoided or else PBMC are isolated from patients by
leukapheresis and stored in liquid nitrogen prior to start-
ing intravenous zoledronate therapy [26, 27, 34]. Similar
anergy and deletion of Vγ2Vδ2 T cells were noted with
intravenous bromohydrin pyrophosphate [32] or zole-
dronate in monkeys (unpublished observations) or in
breast cancer patients receiving zoledronate [33].
Thawed PBMC harvested prior to zoledronate treat-
ments can then be used for ex vivo expansion of
Vγ2Vδ2 T cells for adoptive transfer as we have done in
this study. Thus, for effective anti-tumor immunity it is
insufficient to treat only with aminobisphosphonates,
new populations of Vγ2Vδ2 T cells are also needed
explaining the requirement for repeated cycles of pami-
dronate and Vγ2Vδ2 T cells for control of PC-3 tumor
growth in NSG mice [this study and Ref. 54] or alendro-
nate and Vγ2Vδ2 T cells for control of MeWo melan-
oma and PancTu1 pancreatic adenocarcinoma tumors in
SCID mice [82]. With weekly treatments, PC-3 tumor
growth was completely halted for the duration of treat-
ment with tumor growth resuming two weeks after com-
pletion of therapy (Fig. 4 and 7).
Vγ2Vδ2 T cells expanded with IL-15 and pulse zole-
dronate stimulation showed identical tumor immunity
upon in vivo testing to those expanded with IL-2. Des-
pite preserving a higher proportion of early/central
memory subsets that mediate improved tumor immunity
in mice [45, 83], transfer of Vγ2Vδ2 T cells expanded
with IL-15 inhibited PC-3 tumor growth in NSG mice
identically to equal numbers of Vγ2Vδ2 T cells
expanded with IL-2 (Fig. 7). This finding may reflect the
limitations of the humanized mouse model used in this
study. In the PC-3 model, there are relatively short inter-
vals between the infusions of Vγ2Vδ2 T cells that may
limit the impact of any increase in the persistence of the
Vγ2Vδ2 T cells. Moreover, in the clinical trials with the
best outcomes, intravenous zoledronate was given either
on the day of each cell infusion [27, 34] or one day prior
to and on the day of cell infusion [26]. These approaches
are similar to the one used in our mouse model. In this
model, treatment by adoptive transfer of Vγ2Vδ2 T cells
without pamidronate or giving pamidronate only once
prior to the first cell infusion does not inhibit PC-3
tumor growth. Only when pamidronate is given prior
to each Vγ2Vδ2 T cell infusion is PC-3 tumor growth
significantly controlled [54]. As discussed above, intra-
venous aminobisphosphonates or prenyl pyrophos-
phates rapidly leads to anergy and/or deletion of
Vγ2Vδ2 T cells which would limit the advantage of
increasing their persistence.
Our results are consistent with studies on human CD8
αβ T cells. Melanoma-specific CD8 αβ T cells expand to
a similar degree in high dose IL-2 (300 IU/ml) or IL-15
and produce equal amounts of IFN-γ. Similar results
were observed with CAR-T cells expressing gp100-
reactive TCRs and with naive or adult T cells stimulated
with anti-CD3 [84]. In vitro expansion is also similar
when either high dose IL-2 (1000 IU/ml), IL-15, or a
combination of the two is used for human CD8 αβ T
cells specific for melanoma, influenza, Epstein-Barr
virus, and cytomegalovirus [85]. Importantly, specific
lysis of melanomas and IFN-γ release in response to
melanoma cells is similar [85]. Cytomegalovirus-specific
CD8 αβ T cells also expand similarly with IL-2 or IL-15
and exhibit similar levels of cytotoxicity, IFN-γ and
TNF-α production [86]. These results and ours differ
from the in vitro results using IL-15 with Vγ2Vδ2 T cells
in a recent study [87]. In this study, however, relatively
low dose IL-2 (100 IU/ml) was used, some of the experi-
ments used pure Vγ2Vδ2 T cells omitting accessory cells
or used both IL-2 and IL-15, and the cells were not
tested for their in vivo tumor activity [87].
Our results differ from those reported for murine
models. In the Pmel-1 murine melanoma model, the
majority of Pmel-1 CD8 αβ T cells expressing transgenic
TCRs specific for the self/tumor specific peptide,
gp10025–33 are naive when stimulated in vitro with the
gp10025–33 peptide and either IL-2 or IL-15 [44, 83].
Stimulation differentiates these naive T cells into
enriched populations of effector (IL-2) or central (IL-15)
memory T cells. Pmel-1 T cells expanded in IL-15
exhibit enhanced tumor immunity compared with those
expanded in IL-2 [83]. Similarly, only P14 TCR trans-
genic T cells stimulated with the gp33-44 peptide with
IL-15 mediate tumor immunity to B16gp33 melanoma
cells [45]. T effector generated from naive precursors
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exhibit more anti-tumor immunity than those generated
from memory cells [88] and naive and early effector
tumor-specific murine T cells exhibit more anti-tumor
immunity than effector T cells [62].
This use of naive T cells for generating effector T cells
for transfer is a significant difference between human
Vγ2Vδ2 T cells and murine TCR transgenic T cells that
may explain the difference in IL-15 effects. Essentially all
adult Vγ2Vδ2 T cells are memory cells with only a very
small proportion (1.6%) with naive phenotypes (data not
shown and Ref. [89]). Therefore, most expanded Vγ2Vδ2
T cells are derived from memory Vγ2Vδ2 T cells rather
than naive cells. We speculate that this fact diminishes
the effectiveness of IL-15 because the Vγ2Vδ2 cells
being stimulated are already memory cells rather than
differentiating from naive cells to memory under the
influence of IL-15 whereupon the cells would retain
more early/central memory capabilities.
Thus, we would conclude that expansion of Vγ2Vδ2 T
cells in IL-15 could help persistence in vivo but without
zoledronate treatment to render the tumor cells stimula-
tory to Vγ2Vδ2 T cells, they would have limited ability to
control tumor growth. If zoledronate or another aminobi-
sphosphonate is given, then the Vγ2Vδ2 T cells that are
present will likely be rapidly anergized and/or deleted
limiting the benefits of increased Vγ2Vδ2 T cell survival.
Although in vivo administration of IL-15 could show
benefits by promoting memory T cell survival [59, 90, 91],
we predict that using IL-15 instead of IL-2 for ex vivo
Vγ2Vδ2 T cell expansion is unlikely to show benefits.
To treat patients, cell expansions must be performed in
media produced under cGMP. To confirm that pulse zole-
dronate stimulation would show similar benefits, we com-
pared the results obtained with the enriched RPMI 1640
media used in our experiments (termed C-media) with
OpTmizer™ media, a media meeting cGMP standards.
OpTmizer™ media gives higher numbers of Vγ2Vδ2 T cell
after stimulation with continuous zoledronate stimulation
compared with conventional RPMI 1640 or AIM-V™
media with 1% human serum [92]. Clinical trials in Japan
have used ALys203 - γδ or ALys505 enriched media
(based on Iscove’s DMEM media) with 2-10% autologous
plasma [24, 25, 27–30, 37]. We have also used another
enriched media, Yssel’s media, that is also based on
Iscove’s DMEM [93] with 10% human serum, for expan-
sion with a 24 h zoledronate pulse [33]. PBMC were
incubated with 5 μM zoledronate for 24 h followed by re-
moval of spent media and addition of fresh media such
that the zoledronate concentration was reduced to
0.625 μM. This modified pulse method also gave high
rates of expansion with Vγ2Vδ2 T cells purity of 97%
of T cells at day 10. In the present study, we found
that expansion of Vγ2Vδ2 T cells in C-media with FCS
gave comparable expansions to those obtained in
OpTmizer™ media confirming the utility of this method of
expansion for use with cGMP compliant media.
C-media could be a cost-effective option for preclinical
studies as it is based on inexpensive RPMI 1640 yet gives
comparable results to OpTmizer™ media. In preclinical
studies testing Vγ2Vδ2 T cells in vitro or in vivo in
humanized mouse models, suboptimal expansion of
Vγ2Vδ2 T cells is commonly reported and could be due
to continuous zoledronate stimulation in non-enriched
media. Poor quality Vγ2Vδ2 T cells could skew the
results in these studies. For example, testing novel ami-
nobisphosphonates by Vγ2Vδ2 T cell expansion using
continuous stimulation gave difficult to interpret results
due to toxicity that likely could be avoided by pulsing
[94]. Toxicity differences likely explain the varying levels
of maximal Vγ2Vδ2 T cell expansion observed with
different aminobisphosphonates [15, 95].
Besides limiting exposure to zoledronate, there may be
other ways to improve ex vivo expansion of Vγ2Vδ2 T
cells to generate cells with better anti-tumor immunity.
The mechanistic target of rapamycin (mTOR) kinase
regulates myriad cellular functions including metabol-
ism, protein synthesis, growth, survival, apoptosis, and
autophagy [96, 97]. Inhibition of mTOR with rapamycin
enhances memory CD8 αβ T cell generation and func-
tion [98, 99] through downregulation of T-bet and up-
regulation of Eomesodermin [98, 100]. Rapamycin
enhances anti-tumor responses in murine tumor models
[100, 101]. Moreover, a short treatment with rapamycin
increases the activity of human CD8 αβ T cells upon
adoptive transfer into NSG mice bearing human mela-
nomas [91]. Consistent with these increases in tumor
activity, although long term rapamycin treatment delays
ex vivo expansion, the resulting Vγ2Vδ2 T cells express
higher levels of CD25, less CCR5, and are more cytotoxic
[102]. Therefore, a short treatment of Vγ2Vδ2 T cells with
rapamycin prior to adoptive transfer could enhance their
anti-tumor activity without delaying expansion.
Another possible way to improve anti-tumor immunity
of Vγ2Vδ2 T cells is to alter the cytokines used during
expansion. IL-18 added to IL-2 increases Vγ2Vδ2 T cell
numbers by 2.7-fold after zoledronate stimulation of
PBMC from breast cancer patients and increases the
production of IFN-γ and TNF-α [33]. IL-18 with IL-2
also increases the number of CD56+CD11c+ NK-like
cells [33, 103]. Given that a type of pulse zoledronate
exposure was used, similar increases in numbers and
function will likely occur with the pulse zoledronate
stimulation described in this study. Although Vγ2Vδ2 T
cells grown in IL-15 did not mediate better anti-tumor
immunity, synergistic effects between IL-15 and a sec-
ond γC cytokine, IL-21, have been reported [104–106].
In addition to enhancing T cell proliferation, IL-21
maintains expression of CD28 [105, 106]. Unlike IL-2,
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IL-21 suppresses differentiation of CD8 αβ T cells to
effector memory cells [107]. When given in vivo in mice,
IL-21 boosts anti-tumor immunity [104, 108]. By itself,
IL-21 does not support efficient expansion of Vγ2Vδ2 T
cells and drives them to acquire characteristics of follicular
homing T cells that provide B cell help [109, 110]. How-
ever, the combination of IL-21 and IL-2 supports expan-
sion while also increasing the ability of Vγ2Vδ2 T cells to
kill tumor cells and produce inflammatory cytokines
[111]. Thus, expanding Vγ2Vδ2 T cells with pulse zole-
dronate stimulation and either IL-18/IL-2, IL-21/IL-15, or
IL-21/IL-2 could increase their anti-tumor immunity.
Besides using different cytokines during ex vivo expan-
sion, alternatives exist to using zoledronate for stimula-
tion. Prenyl pyrophosphates, such as HMBPP, are not
toxic for Vγ2Vδ2 T cells and two analogs, bromohydrin
pyrophosphate [23] and 2-methyl-3-butenyl-1-pyrophos-
phate [27, 112], have been used for Vγ2Vδ2 T cell
expansions for clinical trials. However, these compounds
are patented investigational drugs and not approved for
general clinical use. Pharmaceutical grade HMBPP is not
available and there are possible patent issues with its
use. Monoclonal antibodies reactive with CD2 and CD3
[113, 114], CD3 [115], and the γδ TCR [116, 117] or
artificial K562 APCs expressing membrane bound IL-15
with IL-2 and IL-21 [118] have been used to expand γδ T
cells that can then be purified for use either as a mixed γδ
TCR population or as purified Vγ2Vδ2 T cells. However,
the mAbs are not currently approved for clinical use.
Finally, more potent aminobisphosphonates can be used
for expansion of Vγ2Vδ2 T cells by pulse stimulation in-
cluding lipophilic pyridinium bisphosphonates [119] lipo-
philic zoledronate derivatives [120], and bisphosphonate
prodrugs [121].
The results of our in vivo studies point to a critical
role for the tumor and the tumor microenvironment in
preventing Vγ2Vδ2 T cells from completely eliminating
tumors. Despite halting tumor growth for five weeks,
adoptive transfer of Vγ2Vδ2 T cells did not cure estab-
lished PC-3 tumors in NSG mice. Tumor growth
resumed two weeks after cessation of therapy (Fig. 7b).
This is similar to the results in clinical trials with
Vγ2Vδ2 T cells where stable disease is the most com-
mon positive outcome. For example, adoptive transfer of
Vγ2Vδ2 T cells stabilized advanced non-small cell lung
cancer with one patient alive at 4.5 years (5-years
survival is normally only 3%) and >50% of patients alive
at ~2 years (2-years survival with present treatments
is <8%) [25, 35]. Because we transferred purified
Vγ2Vδ2 T cells, there were no human Treg or other
human αβ T cells. Also, NSG mice have no murine B
cells, T cells, or functional NK cells but they do have
myeloid-derived suppressor cells. Thus, the tumor and the
tumor microenvironment likely prevent Vγ2Vδ2 T cells
from completely eliminating tumors suggesting that
treatments targeting these factors would increase
tumor immunity.
Tumors protect against immune attack through a
variety of mechanisms [122, 123]. One likely mechanism
inhibiting Vγ2Vδ2 T cells is tumor expression of ligands
for checkpoint receptors. Effector T cells express a
variety of inhibitory and costimulatory receptors that
control their function. Inhibitory receptors play import-
ant roles in preventing autoimmune responses. These
same receptors also inhibit anti-tumor responses. Block-
ing the action CTLA-4 and PD-1 receptors or their
ligands by mAbs is effective in treating a number of
different tumors including melanoma, NSCLC, bladder
cancer, renal cancer, cancers with mismatch repair
enzyme deficiency, and Hogkin’s lymphoma [124]. Other
inhibitory receptors or their ligands have been identified,
including BTLA (CD272), LAG-3 (CD223), TIM-3
(CD366), TIGIT, VISTA, B7-H3 (CD276), and B7-H4,
that have been found to increase the effectiveness of
anti-PD-1 and anti-CTLA-4 mAbs in mouse models.
Loss of activity of human CAR-T cells against tumor
cells in NSG mice or humans was associated with
expression of multiple inhibitory receptors including
PD-1, BTLA, LAG3, TIM3, and 2B4 [125, 126]. Check-
point receptor blockade with anti-PD-1 or anti-PD-L1
mAbs enhances murine CAR-T tumor immunity in
mouse models [127–129] and human CAR-T immunity
against human lung cancer xenografts in NSG mice
[130]. Vγ2Vδ2 T cells can express PD-1 [131] and BTLA
[132] that inhibit their functions. We have found that
PD-1, CTLA-4, LAG-3, and TIM-3 are all upregulated
after stimulation of Vγ2Vδ2 T cells with zoledronate
such that 60-95% of Vγ2Vδ2 T cells expressed these
receptors by day 7 (data not shown). We hypothesize
that a similar upregulation of inhibitory receptors occurs
in patients treated with zoledronate and Vγ2Vδ2 T cells
because zoledronate treatment would stimulate the
Vγ2Vδ2 T cells. This would limit tumor immunity
provided by the transferred Vγ2Vδ2 T cells.
Besides checkpoint blockade, tumor cells and surround-
ing stromal and immune regulatory cells also produce
various metabolites and cytokines that inhibit effector T
cell function. Indoleamine 2,3-dioxygenase (IDO) isoforms
are rate limiting enzymes in a pathway that catabolizes L-
tryptophan to kynurenine and other toxic metabolites that
inhibit effector T cells [133] while also depleting L-
tryptophan (reviewed in [134, 135]). Tumor expression of
IDO also promotes the differentiation and activation of
Foxp3+ regulatory T cells [reviewed in 135] that serve to
recruit myeloid derived suppressor cells [136]. IDO inhibi-
tors, such as 1-methyl-D-trytophan (indoximod) and
epacadostat, enhance anti-tumor immunity either alone or
in combination with mAbs against CTLA-4 or PD-1 in
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murine models [137–139] or in studies with CD19-
CAR T cells in humanized mouse models [140] and
are presently in clinical trials.
Tumors and mesenchymal stem cells also produce
prostaglandin E2 (PGE2) that inhibits the function of
Vγ2Vδ2 T cells, decreasing their cytotoxicity and pro-
duction of inflammatory cytokines [66, 141–143]. PGE2
is produced through the action of COX1 and COX2
enzymes and COX2 upregulated in a some cancers
[144]. PGE2 protects tumors in mice from T cell
dependent growth control and blocking PGE2 produc-
tion with aspirin synergizes with anti-PD-1 to control
tumor growth [145]. Thus, blocking COX1/COX2 to in-
hibit PGE2 production could enhance the anti-tumor
immunity of Vγ2Vδ2 T cells.
Adoptive immunotherapy with Vγ2Vδ2 T cells could be
an important addition to present cancer treatments.
Although safe, Vγ2Vδ2 T cell therapy has thus far had low
response rates. This therapy has many potential advan-
tages. Vγ2Vδ2 T cell are stimulated by a wide array of
tumors because recognition does not require neoantigens
or tumor-specific proteins or MHC expression but instead
is dependent on alterations in isoprenoid metabolism and
expression of BTN3A1. As discussed above, aminobispho-
sphonate treatment is similar to traditional chemothera-
peutic agents because it targets tumor cells because of
their rapid proliferation and high metabolic activity. But
here the result is elevations of IPP that stimulate Vγ2Vδ2
T cells through their TCRs. Treatment with Vγ2Vδ2 T
cells could be used for a variety of solid tumors or for
those patients that fail other immunotherapies. Unlike αβ
CAR-T cells, no preconditioning of patients with chemo-
therapy or radiation therapy is required. To improve
efficacy, Vγ2Vδ2 T cell therapy could be combined with
checkpoint blockade to enhance the anti-tumor immunity
of transferred Vγ2Vδ2 T cells while also releasing intrinsic
neoantigen-specific αβ T cells. Depending on the tumor,
mAbs targeting different checkpoint receptors could help
improve the effectiveness of Vγ2Vδ2 T cells. Drugs block-
ing IDO or PGE2 synthesis would likely also add to their
effectiveness. Drug treatments or the use of different
cytokines could improve ex vivo Vγ2Vδ2 T cell expansion.
To realize the full potential of Vγ2Vδ2 T cell treatments,
we need to determine what combination of therapies
results in effective tumor control.
Conclusions
Here we describe a modification to ex vivo expansion of
Vγ2Vδ2 T cells that improves adoptive immunotherapy
for prostate cancer in a humanized mice model. Pulse
zoledronate stimulation maximizes the purity, quantity,
and quality of expanded Vγ2Vδ2 cells. This simple
modification to existing protocols will enhance the
effectiveness of adoptively transferred Vγ2Vδ2 T cells.
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